+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epinephrine Autoinjectors - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5028116
The global market for Epinephrine Autoinjectors is estimated at US$2.5 Billion in 2023 and is projected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the 0.15 gm Dosage segment, which is expected to reach US$2.5 Billion by 2030 with a CAGR of 4.6%. The 0.30 gm Dosage segment is also set to grow at 5.6% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $756.1 Million in 2023, and China, forecasted to grow at an impressive 4.5% CAGR to reach $634.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Epinephrine Autoinjectors Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Epinephrine Autoinjectors Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Epinephrine Autoinjectors Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Adamis Pharmaceuticals Corporation, ALK-Abello AS, Antares Pharma, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Adamis Pharmaceuticals Corporation
  • ALK-Abello AS
  • Antares Pharma, Inc.
  • Bausch + Lomb UK Ltd- Emerade
  • Hospira, Inc.
  • Impax Laboratories, Inc.
  • Lincoln Medical
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Epinephrine Auto-injector - Global Key Competitors Percentage Market Share in 2022 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Epinephrine Autoinjectors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 11: World Recent Past, Current & Future Analysis for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for 0.15 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for 0.30 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for 0.5 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
JAPAN
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
CHINA
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
EUROPE
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
FRANCE
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: France Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: France 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
GERMANY
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 61: Germany 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 67: Italy 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 72: UK Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 73: UK 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adamis Pharmaceuticals Corporation
  • ALK-Abello AS
  • Antares Pharma, Inc.
  • Bausch + Lomb UK Ltd- Emerade
  • Hospira, Inc.
  • Impax Laboratories, Inc.
  • Lincoln Medical
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.

Table Information